Build status - In Progress

An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis

Recruiting
99 years or below
All
1 participants needed
1 Location

Brief description of study

This study provides patients with generalized myasthenia gravis (gMG), who are ineligible to participate in a clinical trial, access to efgartigimod treatment before regulatory approval. This expanded access protocol applies to patients with gMG who are not enrolled in an ongoing clinical trial. Enrolled patients will receive cycles of efgartigimod IV 10 mg/kg infused once weekly for 4 infusions.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 12 May 2021. Study ID: 848793

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center